Amneal Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Amneal Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net revenue | 695,420,000 | 730,518,000 | 702,468,000 | 701,780,000 | 659,191,000 | 599,046,000 | 557,540,000 | 609,759,000 | 545,557,000 | 559,355,000 | 497,633,000 | 536,896,000 | 528,593,000 | 535,075,000 | 493,105,000 | 510,034,000 | 519,294,000 | 464,662,000 | 498,533,000 | 397,328,000 | 378,283,000 | 404,642,000 | 446,120,000 | 497,528,000 | 476,487,000 | 413,787,000 | |
| cost of goods sold | 439,529,000 | 467,645,000 | 432,910,000 | 451,833,000 | 421,131,000 | 379,025,000 | 379,354,000 | 389,046,000 | 350,653,000 | 353,724,000 | 323,062,000 | 348,490,000 | 329,394,000 | 322,577,000 | 301,543,000 | 342,962,000 | 353,345,000 | 319,666,000 | 313,578,000 | 273,373,000 | 267,717,000 | 296,381,000 | 309,743,000 | 304,120,000 | 276,382,000 | 235,492,000 | |
| gross profit | 255,891,000 | 262,873,000 | 269,558,000 | 249,947,000 | 238,060,000 | 220,021,000 | 178,186,000 | 215,388,000 | 194,230,000 | 200,519,000 | 174,571,000 | 166,402,000 | 198,511,000 | 212,498,000 | 191,562,000 | 167,072,000 | 133,585,000 | 144,237,000 | 183,499,000 | 110,234,000 | 54,434,000 | 105,249,000 | 83,080,000 | 193,408,000 | 200,105,000 | 178,295,000 | |
| yoy | 7.49% | 22.51% | 40.27% | 10.53% | 9.73% | 2.07% | 29.44% | -2.16% | -5.64% | -8.87% | -0.40% | 48.60% | 47.33% | 4.39% | 51.56% | 145.41% | 37.04% | 120.87% | -43.00% | -72.80% | -40.97% | ||||||
| qoq | -2.66% | -2.48% | 7.85% | 4.99% | 23.48% | -17.27% | 10.89% | -3.14% | 14.86% | 4.91% | -16.17% | -6.58% | 10.93% | 14.66% | 25.07% | -7.39% | -21.40% | 66.46% | 102.51% | -48.28% | 26.68% | -57.04% | -3.35% | 12.23% | |||
| gross margin % | |||||||||||||||||||||||||||
| selling, general and administrative | 118,288,000 | 128,687,000 | 118,692,000 | 116,462,000 | 112,595,000 | 105,570,000 | 102,096,000 | 102,158,000 | 100,071,000 | 98,806,000 | 98,665,000 | 97,224,000 | 91,397,000 | 86,157,000 | 90,726,000 | 84,687,000 | 83,120,000 | 80,944,000 | 77,976,000 | 74,084,000 | 63,797,000 | 67,281,000 | 84,436,000 | 74,236,000 | 78,075,000 | 53,003,000 | |
| research and development | 40,040,000 | 54,265,000 | 61,097,000 | 36,054,000 | 39,298,000 | 37,799,000 | 38,690,000 | 41,907,000 | 50,235,000 | 50,748,000 | 52,798,000 | 51,874,000 | 48,927,000 | 52,864,000 | 48,182,000 | 53,460,000 | 44,519,000 | 45,572,000 | 36,379,000 | 48,050,000 | 38,125,000 | 48,016,000 | 53,858,000 | 56,647,000 | 42,999,000 | 50,335,000 | |
| intellectual property legal development expenses | 1,767,000 | 1,852,000 | 1,967,000 | 1,042,000 | 984,000 | 820,000 | 1,644,000 | 1,362,000 | 1,411,000 | 821,000 | 764,000 | 1,142,000 | 1,627,000 | 1,365,000 | 3,582,000 | 3,701,000 | 2,134,000 | 3,550,000 | 1,270,000 | 4,975,000 | 2,586,000 | 2,511,000 | 4,166,000 | 3,237,000 | 4,401,000 | 4,047,000 | |
| restructuring and other charges | 571,000 | 493,000 | 172,000 | 220,000 | 1,470,000 | 82,000 | 510,000 | 109,000 | 581,000 | 731,000 | 1,069,000 | 425,000 | 363,000 | -259,000 | 276,000 | 333,000 | 2,048,000 | 4,412,000 | 20,937,000 | 2,835,000 | 6,161,000 | ||||||
| charges related to legal matters | 699,000 | 2,017,000 | 20,094,000 | 285,000 | 251,877,000 | 6,000,000 | 19,000,000 | 1,465,000 | 60,000 | 1,300,000 | 4,500,000 | ||||||||||||||||
| other operating income | -5,122,000 | 13,000 | -1,224,000 | -1,465,000 | -1,320,000 | -1,175,000 | |||||||||||||||||||||
| operating income | 100,347,000 | 75,793,000 | 88,809,000 | 95,470,000 | -10,746,000 | 80,084,000 | 34,449,000 | 36,032,000 | 44,353,000 | -198,618,000 | 23,305,000 | 11,175,000 | 28,515,000 | 67,119,000 | 45,907,000 | 20,178,000 | 2,435,000 | 10,751,000 | 57,791,000 | -23,135,000 | -112,274,000 | -18,913,000 | -94,360,000 | 23,280,000 | 74,555,000 | -181,062,000 | |
| yoy | -1033.81% | 10.89% | 177.13% | -129.82% | -140.32% | 47.82% | 222.43% | 55.54% | -395.92% | -49.23% | -44.62% | 1071.05% | 524.30% | -20.56% | -187.22% | -102.17% | -156.84% | -161.25% | -199.38% | -250.59% | -89.55% | ||||||
| qoq | 32.40% | -14.66% | -6.98% | -988.42% | 132.47% | -4.39% | -18.76% | -122.33% | -952.25% | 108.55% | -60.81% | -57.52% | 46.21% | 127.51% | 728.67% | -77.35% | -81.40% | -349.80% | -79.39% | 493.63% | -79.96% | -505.33% | -68.77% | -141.18% | |||
| operating margin % | |||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||
| interest expense | -56,939,000 | -61,662,000 | -65,511,000 | -65,719,000 | -65,703,000 | -50,857,000 | -49,315,000 | -47,028,000 | -42,391,000 | -35,623,000 | -33,335,000 | -33,957,000 | -34,400,000 | -34,083,000 | -33,885,000 | -34,535,000 | -34,895,000 | -36,669,000 | -39,899,000 | -38,829,000 | -42,209,000 | -43,886,000 | -43,281,000 | -42,880,000 | -43,018,000 | -36,622,000 | |
| foreign exchange gain | 4,247,000 | -7,661,000 | 2,274,000 | -262,000 | -1,197,000 | 421,000 | 1,901,000 | -2,013,000 | -170,000 | -29,000 | -2,244,000 | 2,088,000 | 8,392,000 | 9,673,000 | 3,466,000 | 8,311,000 | -5,464,000 | 2,817,000 | -5,137,000 | -25,946,000 | |||||||
| increase in tax receivable agreement liability | -10,687,000 | -23,961,000 | -11,327,000 | -13,444,000 | -1,948,000 | ||||||||||||||||||||||
| other income | 518,000 | 2,172,000 | 1,178,000 | 4,360,000 | 4,072,000 | 12,000 | 3,539,000 | 2,772,000 | 5,709,000 | 7,230,000 | 2,122,000 | 6,633,000 | 3,871,000 | 4,032,000 | 794,000 | 488,000 | 898,000 | 571,000 | 633,000 | -237,000 | 446,000 | 149,000 | 1,107,000 | 2,123,000 | -1,014,000 | 791,000 | |
| total other income | -62,861,000 | -91,112,000 | -73,386,000 | -75,065,000 | -64,776,000 | -50,424,000 | -43,875,000 | -43,687,000 | -42,173,000 | -34,113,000 | -33,226,000 | -27,494,000 | -30,558,000 | -32,295,000 | -31,003,000 | -25,655,000 | -24,324,000 | -32,509,000 | -44,447,000 | -33,976,000 | 138,550,000 | -37,314,000 | -38,820,000 | -38,086,000 | -51,981,000 | -81,444,000 | |
| income before income taxes | 37,486,000 | -15,319,000 | 15,423,000 | 20,405,000 | -75,522,000 | 29,660,000 | -9,426,000 | -7,655,000 | 2,180,000 | -232,731,000 | -9,921,000 | -16,319,000 | -2,043,000 | 34,824,000 | 14,904,000 | -5,477,000 | -21,889,000 | -21,758,000 | 13,344,000 | -57,111,000 | 26,276,000 | -56,227,000 | -133,180,000 | -14,806,000 | 22,574,000 | -262,506,000 | |
| benefit from income taxes | 12,868,000 | 5,423,000 | 3,666,000 | 3,618,000 | 6,156,000 | 668,000 | -1,797,000 | 4,570,000 | 7,350,000 | 4,140,000 | 4,049,000 | 2,648,000 | 359,000 | -26,460,750 | 144,000 | 2,186,000 | -108,173,000 | 7,792,000 | 389,668,000 | -5,701,000 | -1,735,750 | 5,109,000 | |||||
| net income | 24,618,000 | -20,742,000 | 11,757,000 | 16,787,000 | -81,678,000 | 29,683,000 | -10,094,000 | -5,858,000 | -2,390,000 | -240,081,000 | -6,460,000 | -20,459,000 | -6,092,000 | 32,176,000 | 14,545,000 | -6,962,000 | -22,033,000 | -23,944,000 | 121,517,000 | -64,903,000 | -363,392,000 | -50,526,000 | -124,752,000 | -20,330,000 | 17,465,000 | -250,090,000 | |
| yoy | -130.14% | -60.39% | -266.31% | 1294.30% | -112.36% | 56.25% | -71.37% | -60.77% | -846.15% | -144.41% | 193.87% | -72.35% | -234.38% | -88.03% | -89.27% | -93.94% | -52.61% | -197.41% | 219.25% | -2180.69% | -79.80% | ||||||
| qoq | -218.69% | -276.42% | -29.96% | -120.55% | -394.07% | 72.31% | 145.10% | -99.00% | 3616.42% | -68.42% | 235.83% | -118.93% | 121.22% | -308.92% | -68.40% | -7.98% | -119.70% | -287.23% | -82.14% | 619.22% | -59.50% | 513.64% | -216.40% | -106.98% | |||
| net income margin % | |||||||||||||||||||||||||||
| less: net income attributable to non-controlling interests | -12,423,000 | -8,167,750 | -11,913,000 | -10,793,000 | 3,151,000 | -7,839,000 | 3,925,000 | 13,058,000 | 11,948,000 | 33,624,000 | |||||||||||||||||
| net income attributable to amneal pharmaceuticals, inc. | 12,195,000 | -31,081,000 | -156,000 | 5,994,000 | -91,643,000 | 11,917,000 | -6,943,000 | -4,333,000 | -2,689,000 | -120,808,000 | -2,156,000 | -6,377,000 | -4,237,000 | 14,532,000 | 6,706,000 | -3,037,000 | -8,975,000 | -11,996,000 | 115,067,000 | -32,128,000 | -265,006,000 | -16,902,000 | -47,881,000 | -8,768,000 | 6,952,000 | -19,104,000 | |
| net income per share | |||||||||||||||||||||||||||
| basic | 0.04 | -0.07 | 0.02 | 0.08 | -0.03 | -0.02 | -0.8 | -0.01 | 0.028 | -0.03 | 0.1 | 0.05 | |||||||||||||||
| diluted | 0.04 | -0.07 | 0.02 | 0.08 | -0.03 | -0.02 | -0.8 | -0.01 | 0.028 | -0.03 | 0.1 | 0.04 | |||||||||||||||
| weighted-average common shares outstanding: | |||||||||||||||||||||||||||
| basic | 311,054 | 309,647 | 309,117 | 176,136 | 153,738 | 150,944 | 151,393 | 150,993 | 149,892 | 149,290 | 148,996 | 148,013 | |||||||||||||||
| diluted | 323,961 | 309,647 | 318,957 | 176,136 | 154,887 | 150,944 | 151,393 | 150,993 | 149,892 | 149,290 | 151,986 | 151,220 | |||||||||||||||
| change in fair value of contingent consideration | -1,030,000 | 100,000 | -6,364,000 | 2,457,000 | 2,226,000 | -1,425,000 | -270,000 | 200,000 | -100,000 | 300,000 | |||||||||||||||||
| (credit) charges related to legal matters | 23,727,250 | -149,000 | |||||||||||||||||||||||||
| charges (credit) related to legal matters | 94,359,000 | ||||||||||||||||||||||||||
| less: net (income) loss attributable to non-controlling interests | -9,965,000 | -17,766,000 | 30,929,000 | -299,000 | -17,644,000 | -6,450,000 | 5,297,750 | -10,577,000 | |||||||||||||||||||
| net income per share | |||||||||||||||||||||||||||
| basic and diluted | -0.3 | -0.05 | |||||||||||||||||||||||||
| weighted-average common shares outstanding: | |||||||||||||||||||||||||||
| basic and diluted | 308,978 | 307,279 | 152,109 | ||||||||||||||||||||||||
| acquisition, transaction-related and integration expenses | -5,000 | 39,000 | 241,000 | 434,000 | 836,000 | 134,000 | 4,283,000 | 2,802,000 | 3,585,000 | 1,041,000 | 1,787,000 | 2,575,000 | 3,706,000 | 3,131,000 | 3,519,000 | 6,032,000 | 4,945,000 | 2,231,000 | 207,507,000 | ||||||||
| insurance recoveries for property losses and associated expenses | -1,911,000 | ||||||||||||||||||||||||||
| (benefit from) benefit from income taxes | -23,000 | -3,461,000 | -8,428,000 | -12,416,000 | |||||||||||||||||||||||
| net income attributable to amneal pharmaceuticals, inc. before accretion of redeemable non-controlling interest | 11,917,000 | -6,943,000 | -4,333,000 | -2,689,000 | -120,808,000 | -1,718,000 | -32,128,000 | -265,006,000 | -16,902,000 | -8,768,000 | 6,888,000 | -17,864,000 | |||||||||||||||
| accretion of redeemable non-controlling interest | -438,000 | 64,000 | -1,240,000 | ||||||||||||||||||||||||
| credit related to legal matters | -436,000 | -2,326,000 | |||||||||||||||||||||||||
| cost of goods sold impairment charges | 5,325,000 | 674,000 | 5,112,000 | 22,004,000 | 688,000 | 32,364,000 | 759,000 | 1,456,000 | 13,721,000 | 56,132,000 | 3,012,000 | 53,297,000 | |||||||||||||||
| in-process research and development impairment charges | 710,000 | 1,720,000 | 960,000 | 450,000 | 23,382,000 | 22,787,000 | |||||||||||||||||||||
| charges (insurance recoveries) for property losses and associated expenses | -477,750 | ||||||||||||||||||||||||||
| foreign exchange loss | -3,233,250 | -5,491,000 | -5,429,000 | -5,181,000 | -2,421,000 | -12,531,000 | |||||||||||||||||||||
| loss on refinancing | -72,750 | -291,000 | |||||||||||||||||||||||||
| less: net income (income) attributable to non-controlling interests | 119,273,000 | 4,742,000 | -5,907,000 | 1,855,000 | 32,775,000 | 98,386,000 | 76,871,000 | 31,885,000 | |||||||||||||||||||
| property losses and associated expenses | -2,818,000 | 8,186,000 | |||||||||||||||||||||||||
| gain on sale of international businesses | 123,000 | 328,000 | -1,888,000 | ||||||||||||||||||||||||
| gain from reduction of tax receivable agreement liability | 40,000 | 192,844,000 | |||||||||||||||||||||||||
| net income per share | |||||||||||||||||||||||||||
| class a and class b-1 basic | -0.02 | -0.06 | -0.08 | 0.78 | -0.64 | -2.03 | -0.025 | 0.05 | |||||||||||||||||||
| class a and class b-1 diluted | -0.02 | -0.06 | -0.08 | 0.78 | -0.64 | -2.03 | -0.025 | 0.05 | |||||||||||||||||||
| weighted-average common shares outstanding: | |||||||||||||||||||||||||||
| gain on sale of international business | 8,818,000 | ||||||||||||||||||||||||||
| charges (gains) related to legal matters | -2,308,000 | 14,750,000 | |||||||||||||||||||||||||
| loss on extinguishment of debt | -19,667,000 | ||||||||||||||||||||||||||
| less: net income attributable to amneal pharmaceuticals llc pre- combination | |||||||||||||||||||||||||||
| legal settlement gains | |||||||||||||||||||||||||||
| less: net income attributable to amneal pharmaceuticals llc pre-combination | |||||||||||||||||||||||||||
| class a and class b-1 basic and diluted | -0.13 | -0.37 | -0.15 | ||||||||||||||||||||||||
| legal settlement gain | |||||||||||||||||||||||||||
| restructuring (benefit) expenses | 10,577,250 | -2,156,000 | |||||||||||||||||||||||||
| loss on sale of certain international businesses | -146,000 | -2,812,000 | |||||||||||||||||||||||||
| less: net (income) loss attributable to amneal pharmaceuticals llc pre-combination | 37,201,500 | ||||||||||||||||||||||||||
| restructuring expenses | 44,465,000 | ||||||||||||||||||||||||||
| less: net income (income) attributable to amneal pharmaceuticals llc pre-combination | 200,341,000 |
We provide you with 20 years income statements for Amneal Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Amneal Pharmaceuticals stock. Explore the full financial landscape of Amneal Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Amneal Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.